Introduction
============

Cytomegalovirus (CMV) colitis is mostly found in immunocompromised patients (solid organ or hematopoietic stem cell transplant recipients, patients with human immunodeficiency virus \[HIV\] infection, and immunosuppressive drug users, including steroid or chemotherapeutic agents), and it often has a poorer outcome in adults than in children.[@b1-tcrm-13-1585]--[@b6-tcrm-13-1585] In addition, it is frequently noted in patients with known or subsequently new diagnosis of inflammatory bowel disease (IBD).[@b7-tcrm-13-1585]--[@b9-tcrm-13-1585] However, there are few case reports and case series of immunocompetent patients without steroid use.[@b10-tcrm-13-1585]--[@b16-tcrm-13-1585]

The number of CMV colitis cases involving immunocompetent patients has noticeably increased in our hospital over the past few decades. However, the only meta-analysis study of such cases, involving 44 patients with immunomodulating comorbidi ties, and in whom the need for surgical intervention negatively influenced survival, was published in 2005.[@b17-tcrm-13-1585] The differences between immunocompetent and immunocompromised patients and the factors affecting their in-hospital mortality were unknown.

Patients and methods
====================

Patients
--------

Our investigation was approved by Chang Gung Medical Foundation Institutional Review Board on February 20, 2017 (approval document No 201700193B0 "Clinical presentations and outcome of cytomegalovirus infection in gastrointestinal tract") during February 01, 2017--February 01, 2018. Informed consent from individual patients to review the medical records covering patients' data was not required for retrospective studies with the electronic medical record system, by Chang Gung Medical Foundation Institutional Review Board. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in a priori approval by the institution's human research committee.

We retrieved the clinical data of all patients who had pathologically proven CMV colitis from the pathology database in Linkou Chang Gung Memorial Hospital between April 2002 and December 2016. All patients in the study had pathologic specimens obtained by sigmoidoscopy, colonoscopy, or surgical resection. CMV colitis was diagnosed by both CMV inclusion bodies and positive immunohistochemistry (IHC) staining, which was performed with a monoclonal antibody directed against the CMV pp65 antigen (Novocastra™ lyophilized mouse monoclonal antibody; Leica Microsystems, Wetzlar, Germany), as illustrated in [Figure 1](#f1-tcrm-13-1585){ref-type="fig"}.

Steroids are generally considered to be nonspecific immunosuppressants in most studies and textbooks,[@b12-tcrm-13-1585],[@b17-tcrm-13-1585],[@b18-tcrm-13-1585] and the definition of immunocompromised patients in this study is the same as in most reviews or case reports of CMV colitis,[@b9-tcrm-13-1585],[@b17-tcrm-13-1585] except for one previous report.[@b6-tcrm-13-1585] Patients were defined as immunocompromised if they had experienced solid organ or bone marrow transplantation, HIV infection, immunosuppressive drug use (including steroids \[peroral or intravenous route, ≥20 mg per day of prednisone or equivalent for \>2 weeks\]), or chemotherapeutic agent use within 6 months. All other patients were considered immunocompetent.

Clinical data collection
------------------------

For this study, we collected clinical data on a considerable range of presenting symptoms, treatment duration, and outcome parameters, as well as on the following: age, gender, patient source, admission date, diagnostic date, recurrence date, death or last follow-up, general condition within 1 week before diagnosis, underlying diseases, medication history, total white blood cell (WBC) count, absolute neutrophil count (ANC), absolute lymphocyte count (ALC), hemoglobin (Hb), platelet (PLT) count, creatinine (Cr), aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, albumin, C-reactive protein (CRP), CMV pp65 antigenemia, CMV DNA (226 bp segment on glycoprotein B gene, Light-Mix^®^ Kit human Cytomegalovirus; TIB Molbiol, Berlin, Germany), CMV serology, and *Clostridium difficile* infection (BD MAX™ Cdiff Assay; GeneOhm Sciences Canada Inc, Quebec City, QC, Canada). Regarding the classification, "patient source," the designation of intensive care unit (ICU) presents patients who were admitted into the ICU before or during diagnosis in the same admission. "Requisite days of diagnosis" was defined as the duration between admission and diagnosis of CMV colitis. In addition, "recurrence" was defined as the finding of relapsed symptoms and signs with positive IHC stain after the patient had completed antiviral treatment and shown clinical improvement.

Statistical analysis
--------------------

To analyze the differences between the two groups of patients, independent *t*-tests and Mann--Whitney *U* test were used to compare the continuous variables. *χ*^2^ and Fisher's exact tests were employed for the categorical variables. Numerical data were presented as mean ± standard deviation, while categorical data were expressed as absolute numbers and percentages. Logistic regression model was used to identify the independent risk factors for in-hospital mortality. When any factor was found to be significant, via a *P*-value \<0.05 in a univariate analysis, it was put into a multivariate model. The results are presented as odds ratio (OR), 95% CI, and *P*-values. If the continuous variables had clinical significance in the multivariate approach, we modified them into dichotomous variables using the optimal cutoff point as determined by receiver operating characteristic (ROC) curves using the Youden index for further overall survival (OS) evaluation with Kaplan--Meier survival curve analysis, employing a log-rank test. The results were considered to indicate a statistically significant difference when the respective *P*-values were \<0.05. All statistical calculations were performed using SPSS software, version 21 (IBM Corporation, Armonk, NY, USA).

Results
=======

Baseline clinicopathological characteristics
--------------------------------------------

Of the total 69 patients enrolled in the study, 42 (60.87%) were immunocompetent and the remainder were immunocompromised. Three of them had pathologically proven recurrence at the 38th, 63th, and 390th day after the first diagnosis (recurrence rate =4.35%); they received intravenous ganciclovir treatment (10 days, 10 days, and 37 days) and initially clinical symptoms improved. The 44-year-old patient with recurrence on the 38th day had HIV infection. The other two were immunocompetent patients \>70 years old, with multiple comorbidities and critical illness in both CMV colitis episodes.

The average age of all patients was 59.42±20.11 years. As far as general conditions were concerned, \>50% patients in this study had sepsis. Both shock and respiratory failure occurred in 31.9% patients, as summarized in [Table 1](#t1-tcrm-13-1585){ref-type="table"}.

Among the eight patients with IBD after their episode of CMV colitis, two were subsequently diagnosed with ulcerative colitis and one with Crohn's disease. In the systemic lupus erythematosus patients, the C3 and C4 levels were 57.40±17.52 and 15.9±4.45 mg/dL, respectively. Two patients had undergone both renal and liver transplantation under mycophenolate, cyclosporine, and steroid use. Several solid organ malignancies were noted among patients in the study: rectal adenocarcinoma, ureteral urothelial carcinoma, hepatocellular carcinoma, and pancreatic head poorly differentiated adenocarcinoma. Two patients with hematological malignancies were diagnosed with peripheral T cell lymphoma and multiple myeloma. There were eight HIV patients in the study, and their average CD4 count was 50.86±89.80 cells/mm^3^. Five of them (62.5%) were diagnosed with HIV due to CMV colitis events, and three HIV patients (37.5%) were undergoing high levels of active antiretroviral therapy at diagnosis. No CMV colitis patients with bone marrow transplantation were recorded in the study. Other clinical characteristics and laboratory data are summarized in [Table 1](#t1-tcrm-13-1585){ref-type="table"}.

Immunocompetent patients with CMV colitis have more comorbidities
-----------------------------------------------------------------

There were more patients with advanced age (≥65 years), ICU admission, coronary artery disease, and hypertension in the immunocompetent group than those in the immunocompromised group. The former also had significantly longer hospital stays (247.70±795.02 days, 40.00±24.56 days, *P*=0.023). There were no significant differences between these two groups in the laboratory data, except for lower ALC levels in the immunocompromised group.

Different presentations of CMV colitis in different immunological status
------------------------------------------------------------------------

The first presentation of CMV colitis in patients included melena (n=29, 42%), diarrhea (n=28, 40.6%), and abdominal pain (n=8, 11.6%). Four of these cases also first presented as positive stool occult blood (two cases), colonoscopy health examination (one case), and regular follow-up after colectomy due to colon cancer (one case). Although diarrhea (49.3%) and melena (46.4%) were the first and second most common symptoms in patients with CMV colitis, immunological status revealed that melena (47.6%) was the most common first presentation in immunocompetent patients and diarrhea (59.3%) in immunocompromised ones. The details are summarized in [Table 2](#t2-tcrm-13-1585){ref-type="table"}.

CMV reactivation plays a major role in CMV colitis
--------------------------------------------------

The gold standard for diagnosing CMV colitis is histopathology, and negative plasma or whole blood polymerase chain reaction (PCR) does not exclude CMV colitis. In this study, most patients had incomplete laboratory data regarding CMV infection markers ([Table 2](#t2-tcrm-13-1585){ref-type="table"}). Regarding available data, 66.7% patients had CMV of pp65 antigenemia. The CMV IgG-positive rate (94.7%) was far more than the CMV IgM-positive rate (18.4%). Although there was no resultant CMV IgG data, CMV reactivation might play a major role in CMV colitis. However, it did not affect the mortality outcomes in our study.

*C. difficile* coinfection does not worsen the outcome
------------------------------------------------------

CMV colitis has been reported as one of the more significant risk factors for *C. difficile* colonization.[@b19-tcrm-13-1585] However, no study has demonstrated the relationship between coinfection and mortality rate in this context. Four of our patients had evidence of *C. difficile* coinfection and they were equally distributed across the immunocompetent and immunocompromised groups. Although the incidence was higher in the immunocompromised group, it was not statistically significant. Furthermore, *C. difficile* coinfection was not a risk factor for in-hospital mortality (*P*=0.925).

Clinical complications and endoscopic follow-up
-----------------------------------------------

In our study cohort, three patients (4.3%) had perforation and eight (11.6%) needed surgical treatment due to perforation, massive bleeding, or abscess. During follow-up, three patients (4.3%) had stricture and none of them had IBD. The in-hospital mortality and OS rates were 26.1% and 65.22%, respectively.

Only 21 patients had endoscopic follow-up after clinical improvement, and none had an active colonic lesion. Eight patients repeated endoscopic examination due to progressive or recurrent signs and symptoms. Among these, two, one, one, and four patients were IBD cases, HIV host, without treatment (improved after treatment), and with progressive septic shock, respectively; subsequently, two died.

Early diagnosis of CMV colitis improves survival
------------------------------------------------

In univariate analyses, we found that ICU admission, requisite days of diagnosis, shock, respiratory failure, ALC, Hb, Cr, and CRP were statistically significantly associated with in-hospital mortality. However, in multivariate logistic analyses, the requisite days of diagnosis was the only significant independent predictor of in-hospital mortality (OR 1.075, 95% CI 1.005--1.149, *P*=0.035). We then determined the optimal cutoff point of 9 days from admission by further evaluation with ROC curves and the Youden index. Using the Kaplan--Meier survival curve analysis, we found that the patients with diagnosis before 9 days had a significantly better OS rate (log rank *P*=0.018), as shown in [Figure 2](#f2-tcrm-13-1585){ref-type="fig"}. In addition, the patients with immunocompromised status or steroid use had lower in-hospital mortality rates or worse OS outcomes, as illustrated in [Figure 3](#f3-tcrm-13-1585){ref-type="fig"}, with the details summarized in [Table 3](#t3-tcrm-13-1585){ref-type="table"}.

Discussion
==========

Although CMV colitis was considered rare in immunocompetent hosts,[@b20-tcrm-13-1585]--[@b22-tcrm-13-1585] the recent increase in the number of published case reports of this type, especially involving patients with IBD, critical illness, and end-stage renal disease, drew our attention and concern.[@b8-tcrm-13-1585],[@b16-tcrm-13-1585],[@b23-tcrm-13-1585]--[@b25-tcrm-13-1585] However, we could find no study that could predict mortality in such patients. Therefore, we designed the current study to improve this situation.

CMV colitis in immunocompetent patients
---------------------------------------

In this study, there were 42 immunocompetent patients (60.87%) with CMV colitis. This observation notably revealed CMV colitis was not rare in immunocompetent patients. However, 19 of these patients (45.24%) had comorbidities associated with immune dysfunction, including diabetes mellitus, liver cirrhosis, and end-stage renal disease. Ten others had critical conditions, such as ICU admission and respiratory failure or shock, and only 13 patients (30.95%) had no clinical conditions with possible immune dysfunction. Besides, recent studies have shown that mucosal defects can increase the risk of CMV infection.[@b9-tcrm-13-1585],[@b26-tcrm-13-1585] If we further excluded patients with IBD, only eight cases were left. Therefore, most (80.95%) of the immunocompetent patients with CMV colitis had comorbidities associated with immune dysfunction, critical illness, or IBD. In addition, 61.9% of these patients were ≥65 years old, and they potentially had more comorbidities, higher risk for critical illness, and poorer immunological suppression for CMV primary or reactive infection.

The only earlier study of this subject (in 2005), involving 44 such patients, found that 75.2% of them indeed had immunomodulating conditions, including pregnancy, renal failure, diabetes mellitus, and untreated nonhematological malignancies.[@b17-tcrm-13-1585] These findings were mostly compatible with ours, although most of their 44 patients were \<55 years old, while 61.9% of ours were ≥65 years old and had multiple comorbidities.

Although diagnostic-based patient selection and treatment was believed integral to optimal outcomes in patients with CMV colitis who had IBD,[@b27-tcrm-13-1585] no evidence showed a similar benefit for other immunocompetent patients. Our review of severe CMV infection in immunocompetent patients revealed inconclusive results because the improvement observed in some of the patients receiving antiviral agents might be related to the typically self-limiting course of the disease rather than to any antiviral effect.[@b28-tcrm-13-1585] The other concern was to balance between the potential morbidity of CMV colitis and the risk of medical toxicity, especially bone marrow suppression and renal insufficiency. Although 71.43% of immunocompetent patients were given antiviral treatments with an average duration of 22.13 days in this study, in-hospital mortality appeared to be unrelated to whether or not patients received such treatment.

CMV colitis in immunocompromised patients
-----------------------------------------

Among our 27 immunocompromised patients, 66.7% were high-dose steroid users with an average steroid dosage equal to using a total of 993.06 mg of prednisolone within 28 days. In addition, among these 27 patients, we had only eight HIV cases, two solid organ transplantations, and two hematological malignancies. These numbers were lower than we expected. Better supportive care and experimental antiviral treatment before pathological diagnosis might explain this finding. Although antiviral treatment was suggested for the immunocompromised patients with CMV colitis, only 74.07% of them received antiviral treatment in the study. These immunocompromised patients had relatively low levels of WBC, ANC, and ALC, as well as Hb and PLT count; therefore, the bone marrow suppression effect of antiviral agents might be an important concern in medical treatment.

The differences between immunocompetent and immunocompromised patients with CMV colitis
---------------------------------------------------------------------------------------

In the immunocompetent group, the patients were older (*P*=0.009) and had more ICU admissions (*P*=0.021), longer hospital stays (*P*=0.023), more comorbidities (especially coronary artery disease \[*P*=0.019\], and hypertension \[*P*=0.010\]), and also a higher ALC (*P*=0.045), as presented in [Table 1](#t1-tcrm-13-1585){ref-type="table"}. These findings suggest that these patients actually had more comorbidities and worse general condition than our immunocompromised patients. However, the in-hospital mortality OS rates were similar, as detailed in [Table 2](#t2-tcrm-13-1585){ref-type="table"} and [Figure 3](#f3-tcrm-13-1585){ref-type="fig"}. This outcome might be due to more complications of immunosuppressants and immunocompromised diseases, such as HIV and hematological malignancy in the immunocompromised group, negatively influencing their survival rate.

It turned out that the most common first presentation was quite different in the two groups; melena in immunocompetent patients and diarrhea in the immunocompromised patients. The former group included more patients with ICU admission, multiple comorbidities, and medications, leading to a higher risk of bleeding, which might explain the finding. In contrast, for the immunocompromised group, a higher risk of opportunistic coinfection, such as *C. difficile* (7.41% vs 4.76%), might explain the higher percentage of diarrhea. If clinicians are more aware of the different presentations and their implications, early diagnosis of CMV colitis could lead to a lower in-hospital mortality rate.

The duration of antiviral therapy depended on the patient and the severity of the disease. In our study, immunocompromised patients received longer treatment durations (23.80±32.39 vs 22.13±11.05 days), but there was no statistically significant difference in in-hospital mortality (*P*=0.069). The complication rate, in-hospital mortality, and OS were also not significantly different.

The predictors of in-hospital mortality in CMV colitis patients
---------------------------------------------------------------

Although early diagnosis reduced in-hospital mortality and improved OS, antiviral treatment did not have these effects. This result might be related to underlying disease and general conditions as well as the timing and toxicity of the treatment. Furthermore, the virus might be nonpathogenic; thus, antiviral treatment is unhelpful.[@b27-tcrm-13-1585] Therefore, we should evaluate clinical conditions individually to decide on the use of antiviral agents instead of treating everyone alike.

The limitations of the study
----------------------------

Although this investigation was the largest single study of CMV colitis based on a histopathological diagnosis until now, a prospective study with more cases is still needed. Besides, better immunological biomarkers of immunocompetence, including complement and immunoglobulin level, will be our further study target.

Conclusion
==========

Contrary to data published up to this point, we found that CMV colitis was not rare and that it could be fatal in immunocompetent hosts, especially those patients with advanced age, specific comorbidities associated with immune dysfunction, critical illness, or IBD. Melena was the most common symptom found in this class of patients, but in contrast, diarrhea was the most common symptom in those who were immunocompromised. Being alert to the different presentations can greatly help make an accurate early diagnosis and materially improve survival for CMV colitis patients.
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![Pathological presentations of CMV colitis.\
**Notes:** CMV colitis was diagnosed by both CMV inclusion bodies and positive IHC staining in the colonic tissue. (**A**) H&E stain (40× objective) showed typical intranuclear (owl's eye) and intracytoplasmic (eosinophilic punctiform) CMV inclusions within the circles. (**B**) IHC stain (20× objective) was performed with 1:200 diluted Novocastra™ lyophilized mouse monoclonal antibody against CMV pp65 antigen and showed strong focal CMV immunoreactivity with brownish areas.\
**Abbreviations:** CMV, cytomegalovirus; H&E, hematoxylin and eosin; IHC, immunohistochemistry.](tcrm-13-1585Fig1){#f1-tcrm-13-1585}

![The survival curves of CMV patients with different requisite days of diagnosis.\
**Notes:** \**P*\<0.05. The number of requisite days of diagnosis (defined as the duration between admission and diagnosis of CMV colitis \[Tdx\]) from admission was the only predictor of in-hospital mortality. With the ROC curve and Youden index, we obtained the cutoff point of 9 days from a Kaplan--Meier survival curve analysis. The patients with diagnosis before 9 days from admission (dashed line) had significantly better OS than the ones who were diagnosed as CMV colitis after 9 days from admission (solid line).\
**Abbreviations:** CMV, cytomegalovirus; OS, overall survival; ROC, receiver operating characteristic.](tcrm-13-1585Fig2){#f2-tcrm-13-1585}

![The survival curves of CMV colitis patients with different immunological status and steroid use.\
**Notes:** (**A**) Immunocompetent (dashed line) and immunocompromised (solid line) patients with CMV colitis had similar OS according to Kaplan--Meier survival curve analysis. (**B**) Nonsteroid users (dashed line) and steroid users (solid line) with CMV colitis had similar OS according to a Kaplan--Meier survival curve analysis.\
**Abbreviations:** CMV, cytomegalovirus; OS, overall survival.](tcrm-13-1585Fig3){#f3-tcrm-13-1585}

###### 

Baseline characteristics of patients with CMV colitis

  Characteristics                                                                       Overall (n=69)      Immunocompetent (n=42)   Immunocompromised (n=27)   *P*-value
  ------------------------------------------------------------------------------------- ------------------- ------------------------ -------------------------- ----------------------------------------------------
  Age, years                                                                            59.42±20.11         64.40±19.36              51.67±19.08                0.009[\*](#tfn1-tcrm-13-1585){ref-type="table-fn"}
  Age ≥65 years                                                                         33 (47.8%)          26 (61.9%)               7 (25.9%)                  0.004[\*](#tfn1-tcrm-13-1585){ref-type="table-fn"}
  Gender (male/female)                                                                  42/27               24/18                    18/9                       0.429
  Patient source                                                                                                                                                
   Outpatient department                                                                6 (8.7%)            5 (11.9%)                1 (3.7%)                   0.392
   Intensive care unit                                                                  27 (39.1%)          21 (50%)                 6 (22.2%)                  0.021[\*](#tfn1-tcrm-13-1585){ref-type="table-fn"}
  Requisite days of diagnosis                                                           22.69±19.18         23.51±20.67              21.42±16.98                0.807
  Hospital stay (days)                                                                  161.98±614.71       247.70±795.02            40.00±24.56                0.023[\*](#tfn1-tcrm-13-1585){ref-type="table-fn"}
  General condition                                                                                                                                             
   Sepsis                                                                               46 (66.7%)          28 (66.7%)               18 (66.7%)                 1.000
   Shock                                                                                22 (31.9%)          13 (31%)                 9 (33.3%)                  0.836
   Respiratory failure                                                                  22 (31.9%)          15 (35.7%)               7 (25.9%)                  0.394
  Underlying diseases                                                                                                                                           
   Inflammatory bowel disease                                                           8 (11.6%)           7 (16.7%)                1 (3.7%)                   0.136
   Ulcerative colitis                                                                   7 (10.1%)           6 (14.3%)                1 (3.7%)                   0.233
   Crohn's disease                                                                      1 (1.4%)            1 (2.4%)                 0 (0%)                     1.000
   Systemic lupus erythematosus                                                         5 (7.2%)            1 (2.4%)                 4 (14.8%)                  0.073
   Solid organ transplantation                                                          2 (2.9%)            0 (0%)                   2 (7.4%)                   0.150
   Solid organ malignancy                                                               4 (5.8%)            1 (2.4%)                 3 (11.1%)                  0.292
   Hematological malignancy                                                             2 (2.9%)            0 (0%)                   2 (7.4%)                   0.150
   Liver cirrhosis                                                                      4 (5.8%)            2 (4.8%)                 2 (7.4%)                   0.641
  Cardiovascular disease                                                                                                                                        
   Coronary artery disease                                                              8 (11.6%)           8 (19.0%)                0 (0%)                     0.019[\*](#tfn1-tcrm-13-1585){ref-type="table-fn"}
   Congestive heart failure                                                             7 (10.1%)           5 (11.9%)                2 (7.4%)                   0.697
  COPD                                                                                  3 (4.3%)            2 (4.8%)                 1 (3.7%)                   1.000
  Renal disease                                                                                                                                                 
   Acute kidney injury                                                                  21 (30.4%)          14 (33.3%)               7 (25.9%)                  0.514
   Chronic kidney disease                                                               13 (18.8%)          6 (14.3%)                7 (25.9%)                  0.228
   End-stage renal disease                                                              8 (11.6%)           6 (14.3%)                2 (7.4%)                   0.467
  Neurological disease                                                                                                                                          
   Stroke                                                                               10 (14.5%)          8 (19.0%)                2 (7.4%)                   0.295
   Parkinsonism                                                                         6 (8.7%)            5 (11.9%)                1 (3.7%)                   0.392
   Epilepsy                                                                             7 (10.14%)          6 (14.29%)               1 (3.7%)                   0.233
  Thyroid disease                                                                       4 (5.8%)            3 (7.1%)                 1 (3.7%)                   1.000
  Diabetes mellitus                                                                     21 (30.4%)          15 (35.7%)               6 (22.2%)                  0.235
  Hypertension                                                                          23 (33.3%)          19 (45.2%)               4 (14.8%)                  0.010[\*](#tfn1-tcrm-13-1585){ref-type="table-fn"}
  HIV infection                                                                         8 (11.6%)           0 (0%)                   8 (29.6%)                  
  Immunosuppressive medication                                                                                                                                  
   Chemotherapy                                                                         1 (1.4%)            0 (0%)                   1 (3.7%)                   
   Steroids                                                                             18 (26.1%)          0 (0%)                   18 (66.7%)                 
   Steroid use over 1 month before diagnosis of CMV colitis                             7 (10.1%)           0 (0%)                   7 (25.9%)                  
  Total prednisolone dosage within 1 month before diagnosis of CMV colitis, mg (n=18)   993.06±1,338.72     0                        993.06±1,338.72            
  Other immunosuppressants                                                              6 (8.7%)            0 (0%)                   6 (22.2%)                  
  Laboratory data                                                                                                                                               
   Total WBC count (/μL)                                                                8,187.31±4,240.07   8,437.80±3,828.82        7,792.31±4,872.53          0.344
   ANC (/μL)                                                                            6,309.84±3,974.94   6,350.70±3,768.83        6,246.97±4,349.18          0.823
   ALC (/μL)                                                                            1,134.22±843.45     1,297.15±925.25          883.57±637.46              0.045[\*](#tfn1-tcrm-13-1585){ref-type="table-fn"}
   Hemoglobin level (g/dL)                                                              10.66±2.24          10.97±2.42               10.18±1.85                 0.203
   Platelet count (×1,000/mm^3^)                                                        239.38±113.48       243.70±92.69             232.73±141.43              0.355
   Creatinine (mg/dL)                                                                   1.88±1.78           1.94±1.66                1.80±1.97                  0.374
   ALT (IU/L)                                                                           23.90±16.64         20.57±12.39              28.56±20.61                0.179
   Bilirubin (mg/dL)                                                                    1.26±1.84           1.22±1.66                1.32±2.12                  0.598
   Albumin (g/dL)                                                                       2.64±0.66           2.63±0.67                2.65±0.65                  0.967
   C-reactive protein (mg/dL)                                                           71.14±72.91         60.90±56.15              87.72±93.19                0.591
   Bacteremia                                                                           16 (23.2%)          8 (19%)                  8 (29.6%)                  0.393
   Fungemia                                                                             5 (7.2%)            3 (7.1%)                 2 (7.4%)                   1.000

**Notes:**

*P*\<0.05. Numerical data were presented as mean ± standard deviation, while categorical data were expressed as absolute number (percentage). Requisite days of diagnosis was defined as the duration between admission and diagnosis of CMV colitis.

**Abbreviations:** ALC, absolute lymphocyte count; ALT, alanine aminotransferase; ANC, absolute neutrophil count; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; WBC, white blood cell.

###### 

Clinical presentations of CMV colitis

  Characteristics                        Overall (n=69)   Immunocompetent (n=42)   Immunocompromised (n=27)   *P*-value
  -------------------------------------- ---------------- ------------------------ -------------------------- ----------------------------------------------------
  Chief complaint                                                                                             
   GI symptoms                           31 (44.9%)       19 (45.2%)               12 (44.4%)                 0.948
   Heart symptoms                        5 (7.2%)         4 (9.5%)                 1 (3.7%)                   0.641
   Sepsis                                24 (34.8%)       13 (31%)                 11 (40.7%)                 0.405
  First presentation                                                                                          
   Melena                                29 (42%)         20 (47.6%)               9 (33.3%)                  0.241
   Diarrhea                              28 (40.6%)       12 (28.6%)               16 (59.3%)                 0.011[\*](#tfn3-tcrm-13-1585){ref-type="table-fn"}
   Pain                                  8 (11.6%)        7 (16.7%)                1 (3.7%)                   0.136
  Symptoms                                                                                                    
   Melena                                32 (46.4%)       22 (52.4%)               10 (37%)                   0.212
   Diarrhea                              34 (49.3%)       15 (35.7%)               19 (70.4%)                 0.005[\*](#tfn3-tcrm-13-1585){ref-type="table-fn"}
   Pain                                  16 (23.2%)       12 (28.6%)               4 (14.8%)                  0.248
   Fever                                 33 (47.8%)       17 (40.5%)               16 (59.3%)                 0.127
  Viral markers                                                                                               
   CMV pp65 antigenemia (n=33, 18, 15)   22 (66.7%)       10 (55.6%)               12 (80%)                   0.266
   Positive (/500,000 PMN)               87.23±183.46     58.00±144.48             111.58±213.90              0.346
   CMV PCR positive (n=8, 4, 4)          4 (50%)          2 (50%)                  2 (50%)                    1.000
   CMV IgG positive (n=38, 23, 15)       36 (94.7%)       22 (95.7%)               14 (93.3%)                 1.000
   CMV IgM positive (n=38, 23, 15)       7 (18.4%)        5 (21.7%)                2 (13.3%)                  0.681
  Medical treatment                                                                                           
   Ganciclovir or valganciclovir         50 (72.46%)      30 (71.43%)              20 (74.07%)                0.810
   Ganciclovir, iv, only                 28 (40.6%)       18 (42.9%)               10 (37.0%)                 0.631
   Valganciclovir, po, only              12 (17.4%)       6 (14.3%)                6 (22.2%)                  0.396
   Ganciclovir and valganciclovir        10 (14.5%)       6 (14.3%)                4 (14.8%)                  1.000
   Duration (days)                       22.80±21.90      22.13±11.05              23.80±32.39                0.069
  Outcome                                                                                                     
   Perforation                           3 (4.3%)         2 (4.8%)                 1 (3.7%)                   1.000
   Surgical                              8 (11.6%)        6 (14.3%)                2 (7.4%)                   0.467
   In-hospital mortality                 18 (26.1%)       11 (26.2%)               7 (25.9%)                  0.981
   Overall survival                      45 (65.22%)      28 (66.67%)              17 (62.97%)                0.753

**Notes:**

*P*\<0.05. Numerical data were presented as mean ± standard deviation, while categorical data were expressed as absolute number (percentage).

**Abbreviations:** CMV, cytomegalovirus; GI, gastrointestinal; iv, intravenous; PCR, polymerase chain reaction; PMN, polymorphonuclear leukocyte; po, per oral.

###### 

Analysis of the clinical factors associated with in-hospital mortality in all patients

  Characteristics                                                                        OR            95% CI            *P*-value
  -------------------------------------------------------------------------------------- ------------- ----------------- ----------------------------------------------------
  **Univariate analysis**                                                                                                
  Age ≥65 years                                                                          2.071         0.691--6.209      0.194
  Gender (male/female)                                                                   0.545         0.184--1.619      0.275
  Immunocompromised status                                                               0.986         0.328--2.969      0.981
  Intensive care unit admission                                                          6.871         2.068--22.833     0.002[\*](#tfn5-tcrm-13-1585){ref-type="table-fn"}
  Requisite days of diagnosis                                                            1.034         1.002--1.066      0.034[\*](#tfn5-tcrm-13-1585){ref-type="table-fn"}
  General condition                                                                                                      
   Sepsis                                                                                1.039×10^9^   0.000--\>10^12^   0.998
   Shock                                                                                 5.714         1.793--18.210     0.003[\*](#tfn5-tcrm-13-1585){ref-type="table-fn"}
   Respiratory failure                                                                   4.062         1.309--12.610     0.015[\*](#tfn5-tcrm-13-1585){ref-type="table-fn"}
   Operation before diagnosis                                                            3.200         0.583--17.553     0.180
  Underlying diseases                                                                                                    
   Inflammatory bowel disease                                                            0.000         0.000             0.999
   Systemic lupus erythematosus                                                          4.900         0.747--32.123     0.098
   Solid organ transplantation                                                           2.941         0.174--49.636     0.454
   Solid organ malignancy                                                                0.941         0.092--9.671      0.959
   Hematological malignancy                                                              2.941         0.174--49.636     0.454
   Liver cirrhosis                                                                       0.941         0.092--9.671      0.959
   Chronic kidney disease                                                                2.067         0.576--7.421      0.265
   End-stage renal disease                                                               3.357         0.742--15.181     0.116
   Diabetes mellitus                                                                     1.682         0.543--5.205      0.367
   HIV infection                                                                         0.000         0.000--.10^12^    0.999
  Immunosuppressive medication                                                                                           
   Immunosuppressant                                                                     3.200         0.583--17.553     0.180
   Chemotherapy                                                                          4.846×10^9^   0.000--.10^12^    1.000
   Steroids                                                                              1.124         0.336--3.764      0.849
   Steroid use over 1 month before diagnosis of CMV colitis                              2.350         0.472--11.708     0.297
   Total prednisolone dosage within 1 month before diagnosis of CMV colitis, mg (n=18)   1.000         0.999--1.001      0.775
  Laboratory data                                                                                                        
   Total WBC count (/μL)                                                                 1.000         1.000--1.000      0.419
   ANC (/μL)                                                                             1.000         1.000--1.000      0.254
   ALC (/μL)                                                                             0.999         0.998--1.000      0.018[\*](#tfn5-tcrm-13-1585){ref-type="table-fn"}
   Hemoglobin level (g/dL)                                                               0.668         0.485--0.918      0.013[\*](#tfn5-tcrm-13-1585){ref-type="table-fn"}
   Platelet count (×1,000/mm^3^)                                                         0.995         0.990--1.001      0.100
   Creatinine (mg/dL)                                                                    1.448         1.059--1.978      0.020[\*](#tfn5-tcrm-13-1585){ref-type="table-fn"}
   ALT (IU/L)                                                                            0.995         0.958--1.033      0.787
   Bilirubin (mg/dL)                                                                     1.370         0.965--1.944      0.078
   Albumin (g/dL)                                                                        0.625         0.231--1.687      0.354
   C-reactive protein (mg/dL)                                                            1.009         1.000--1.018      0.047[\*](#tfn5-tcrm-13-1585){ref-type="table-fn"}
  Viral markers                                                                                                          
   CMV pp65 antigenemia                                                                  0.656         0.140--3.079      0.593
   CMV IgG positive                                                                      0.286         0.016--5.095      0.394
   CMV IgM positive                                                                      3.125         0.547--17.841     0.200
  *C. difficile* infection                                                               0.889         0.077--10.300     0.925
  Ganciclovir or valganciclovir treatment                                                2.286         0.579--9.026      0.238
   Treatment duration                                                                    0.989         0.953--1.026      0.563
  Surgical treatment                                                                     1.840         0.392--8.630      0.439
  Perforation                                                                            1.441         0.123--16.920     0.771
  **Multivariate analysis**                                                                                              
  Intensive care unit admission                                                          4.726         0.374--59.747     0.230
  Requisite days of diagnosis                                                            1.075         1.005--1.149      0.035[\*](#tfn5-tcrm-13-1585){ref-type="table-fn"}
  Shock                                                                                  4.905         0.596--40.362     0.139
  Respiratory failure                                                                    0.661         0.053--8.269      0.748
  ALC (/μL)                                                                              0.998         0.996--1.001      0.157
  Hemoglobin level (g/dL)                                                                0.787         0.459--1.349      0.383
  Creatinine (mg/dL)                                                                     0.618         0.306--1.246      0.179
  C-reactive protein (mg/dL)                                                             1.009         0.998--1.021      0.106

**Notes:**

*P*\<0.05. Requisite days of diagnosis was defined as the duration between admission and diagnosis of CMV colitis.

**Abbreviations:** ALC, absolute lymphocyte count; ALT, alanine aminotransferase; ANC, absolute neutrophil count; *C. difficile*, *Clostridium difficile*; CMV, cytomegalovirus; HIV, human immunodeficiency virus; OR, odds ratio; WBC, white blood cell.
